Lupus & antiphospholipid syndrome
The effects of menopausal hormone therapy for the risk of systemic lupus erythematosus: A nationwide cohort study in Korea
Main finding · Incident SLEResult — go to the resultHazard ratio 1.114 95 % CI 0.88–1.41Authors' conclusion
The utilization of MHT did not demonstrate a substantial impact on the development of SLE in postmenopausal women.
Study context
- Population
- Women aged >40 years seeking healthcare for menopause in Korea, 2011–2014, followed until December 31, 2020
- Participants
- 452,124 women139,331 matched pairs
- Exposure
- Menopausal hormone therapy (MHT) vs non-MHT
- MHTn = 139,197
- non-MHTn = 139,188reference
- Outcome
- Occurrence of SLE (ICD-10 criteria)
Methodological detailspopulation-based, nationwide, propensity score matching
- Population-based
- Nationwide
- Propensity score matching
Main finding
Incident SLE · median follow-up 7.9 [6.9-8.9] years
Hazard ratio
1.114
95 % CI 0.88–1.41
Events by group
MHTvs non-MHT
HR 1.114 (95 % CI 0.88–1.41)
As reported in the abstract
Observational data: associations, not effects.
Further findings
Systemic lupus erythematosus (SLE) with tibolone use within 3 years (subgroup)
| HR (95 % CI) | ||
|---|---|---|
| Tibolone within 3 years | 1.45 (1.051–2.001) | |
| 0.512Hazard ratio (log scale) |
SLE by type and duration of MHT (subgroups)
- No significant differences based on type of MHT or duration of MHT use, except tibolone
Original publication
The effects of menopausal hormone therapy for the risk of systemic lupus erythematosus: A nationwide cohort study in Korea. Semin Arthritis Rheum. Published 30 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →